KBC Group
TVTX icon

KBC Group’s Travere Therapeutics TVTX Stock Holding History

KBC Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$167K Hold
2,843
– – ﹤0.01% 1100
2026
Q2 		$162K Hold
2,843
– – ﹤0.01% 1129
2026
Q1 		$84K Sell
2,843
-1,344
-32% -$40.2K ﹤0.01% 1426
2025
Q4 		$160K Hold
4,187
– – ﹤0.01% 1004
2025
Q3 		$100K Hold
4,187
– – ﹤0.01% 1263
2025
Q2 		$62K Hold
4,187
– – ﹤0.01% 1488
2025
Q1 		$75K Buy
+4,187
New +$85K ﹤0.01% 1639

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

KBC Group's TVTX Position: Q3 2026 in Review

KBC Group held its Travere Therapeutics (TVTX) position steady in Q3 2026 at 2,843 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

KBC Group first reported a position in TVTX in Q1 2025 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • KBC Group held 2,843 shares of Travere Therapeutics worth $167K as of Q3 2026.
  • KBC Group left its Travere Therapeutics share count unchanged in Q3 2026.
  • Travere Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1100 holding.
  • KBC Group first reported a position in Travere Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.